Your email has been successfully added to our mailing list.

×
0.00792899408284015 0.0276134122287968 0.0216962524654833 0.0295857988165681 0.0276134122287968 0.0137869822485206 0.019723865877712 0.0157790927021696
Stock impact report

Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine

ZIOPHARM Oncology Inc (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
Company Research Source: GlobeNewswire
– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma –– Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased tumor infiltrating lymphocytes and PD-1 (programmed cell death protein 1) support immunological anti-tumor effect of Controlled IL-12 –   BOSTON, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the publication of its phase 1 trial of Controlled IL-12 in patients with recurrent glioma in the journal Science Translational Medicine. The publication entitled, “Regulatable interleukin 12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial” can be accessed at https://stm.sciencemag.org/. While IL-12 is known as a potent immune activator that triggers T cells to target cancer, historic trials sy Show less Read more
Impact Snapshot
Event Time:
ZIOP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ZIOP alerts
Opt-in for
ZIOP alerts

from News Quantified
Opt-in for
ZIOP alerts

from News Quantified